Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results
13 août 2024 07h00 HE
|
Mersana Therapeutics, Inc.
Dose escalation advancing in Phase 1 clinical trials of both XMT-1660 and XMT-2056 Continue to expect to announce initial XMT-1660 clinical data and initiate expansion in the second half of 2024 ...
Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024
06 août 2024 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present at Upcoming Investor Conferences
22 mai 2024 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
09 mai 2024 06h59 HE
|
Mersana Therapeutics, Inc.
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 mai 2024 16h30 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
02 mai 2024 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 avr. 2024 16h30 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
28 févr. 2024 07h00 HE
|
Mersana Therapeutics, Inc.
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660; expect to initiate tumor-specific expansion cohorts in the second quarter of 2024 and announce...
Mersana Therapeutics to Present at Upcoming Investor Conferences
27 févr. 2024 08h01 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
21 févr. 2024 08h00 HE
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...